Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Respiratory Drugs >  Expectorants >  Mesna


Basic information Safety Related Supplier
Mesna Basic information
  • Product Name:Mesna
  • CAS:19767-45-4
  • MF:C2H5NaO3S2
  • MW:164.18
  • EINECS:243-285-9
  • Mol File:19767-45-4.mol
Mesna Chemical Properties
  • Melting point:>240°C dec.
  • storage temp. -20?C Freezer, Under Inert Atmosphere
  • solubility Freely soluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in cyclohexane
  • form neat
  • Water Solubility Soluble in water. Also soluble in methanol, DMSO (33 mg/ml) and ethanol (<1 mg/ml).
  • Merck 14,5909
  • BRN 3657828
  • Stability:Stable. Incompatible with strong oxidizing agents.
  • CAS DataBase Reference19767-45-4(CAS DataBase Reference)
Safety Information
  • Hazard Codes Xi
  • Risk Statements 36/37/38
  • Safety Statements 26-36
  • WGK Germany 2
  • RTECS KI7968000
  • HS Code 2930 90 98
  • ToxicityLD50 in male, female mice, male, female rats (mg/kg): 1887, 2048, 2098, 1683 i.v.; 2005, 2098, 1529, 1251 i.p.; 6102, >7200, 4440, 4679 orally (Brock)
Mesna Usage And Synthesis
  • Chemical PropertiesWhite to Off-White Solid
  • OriginatorMistabronco,UCB,W. Germany,1973
  • Usesadrenergic agonist, coronary vasodilator, Ca channel blocker
  • UsesMesna reacts with acrolein and other urotoxic metabolites of oxazaphosphorines (cyclophosphamide or ifosfamide) to form stable, non-urotoxic compounds. Mesna does not have any antitumour activity, nor does it appear to interfere with the antitumour activity of antineoplastic drugs. This medication is used to protect the bladder wall from the harmful effects of some cancer-fighting drugs.
  • Uses2-Mercaptoethanesulfonic acid sodium salt (Coenzyme M sodium salt, MESNA) is used as an antioxidant and cytoprotective agent in a wide variety of applications from protection from toxicity of therapeutic agents, such as cyclophosphamide to prevention from brain injury damage.
  • Manufacturing Process2,100 g of β-S-thiuronium ethanesulfonate were placed in a solution of 2,100 cc of concentrated aqueous ammonia and 400 cc of water. The mixture was carefully warmed on a steam bath and an exothermic reaction ensured, at which point the β-S-thiuronium ethanesulfonate passed into solution. After standing for two hours at room temperature, the solution was concentrated until all of the excess ammonia had been removed.
    The resultant clear solution from the ammonolysis reaction was processed through "Amberlite IR-120" ion exchange resin and converted into β-Smercaptoethanesulfonic acid in 93.7% yield (based on β-S-thiuronium ethanesulfonate).
    It is expedient not to heat the reaction mixture rapidly since this increases the loss of ammonia and effects an incomplete reaction. Heating the mixture too rapidly may retard the ammonolysis reaction entirely. The amount of ammonia used is considered to be a satisfactory minimum and larger quantities of ammonia are not found to have any beneficial effect on the reaction. It is also expedient to remove the excess ammonia before processing the guanidinium β-mercaptoethanesulfonate solution through the ion exchange resin since the resin will also remove the ammonia with the result that the capacity of the resin for the exchange of guanidinium ions will be reduced.
    Although the preparation of β-mercaptoethanesulfonic acid through the ammonolysis reaction is the preferred method, it is also possible to prepare the sulfonic acid by the sodium hydroxide hydrolysis of β-S-thiuronium ethanesulfonate followed by the ion exchange treatment. The resulting acid, however, is generally not as satisfactory as that prepared by the ammonolysis reaction.
  • brand nameAusobrone;Mexnex;Mistabronco;Mistabronco;Mistalon;Mucofluid;Mucolene;Uromitexan;Uronexitan.
  • Therapeutic FunctionMucolytic
  • World Health Organization (WHO)Mesna, an antidote used to protect patients treated with cyclophosphamide or ifosfamide from haemorrhagic vesiculitis, was introduced on the market in 1984. Shortly afterwards, its use became associated with allergic reactions, which occurred mainly in patients treated with the oral solution. This led to the withdrawal of this formulation in Germany, the only country where it was marketed. An oral liquid dosage form is still registered, but not marketed, in the Netherlands and products for intravenous injection remain available elsewhere.
  • Contact allergensMesna is used as a mucolytic agent, and as an antidote to chloro-acetyl-aldehyde and acrolein (a bladder toxic metabolite of ifosfamide or cyclophosphamide). It hasbeen reported as a cause of occupational allergic (hand and airborne) dermatitis in nurses
  • Purification MethodsIt can be recrystallised from H2O and does not melt below 250o. It is purified further by converting to the free acid by passing a 2M solution through an ion-exchange (Amberlite IR-120) column in the acid form, evaporating the eluate in a vacuum to give the acid as a viscous oil (readily decomposes) which can be checked by acid and SH titration. It is then dissolved in H2O, carefully neutralised with aqueous NaOH, evaporated and the salt recrystallised from H2O [Schramm J Am Chem Soc 77 6231 1955]. [Beilstein 4 IV 85.]
Mesna(19767-45-4)Related Product Information
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Company Name:Meryer (Shanghai) Chemical Technology Co., Ltd.
  • Tel:400-660-8290 21-61259100-
  • Company Name:Chembest Research Laboratories Limited
  • Tel:021-20908456-
  • Company Name:TCI (Shanghai) Development Co., Ltd.
  • Tel:021-67121386 / 800-988-0390
  • Company Name:BeiJing Hwrk Chemicals Limted
  • Tel:18600197062 0757-86311057-